Monopar Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$106.60(as of Jul 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Monopar Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$106.60
Ticker SymbolMNPR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees22
CountyUSA
Market Cap$714.1M
EBIDTAUnknown
10-Day Moving Average97.04
P/E Ratio-60.72
20-Day Moving Average83.60
Forward P/E Ratio0.00
50-Day Moving Average69.64
Earnings per Share-1.93
200-Day Moving Average69.50
Profit Margin-Infinity%
RSI83.39
Shares Outstanding6.7M
ATR6.88
52-Week High112.57
Volume149,300
52-Week Low29.18
Most Recent Support Level88.33
Book Value135.4M
Most Recent Resistance Level112.57
P/B Ratio6.72
Upper Keltner99.08
P/S RatioInfinity
Lower Keltner68.12
Debt-to-Equity Ratio99.08
Next Earnings Date08/10/2026
Cash Surplus50.1M
Next Ex-Dividend DateUnknown

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Inc In Our Stock Scanner

As of Jul 13, 2026
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.